3- to 24-month Follow-up on COVID-19 with Pulmonary Tuberculosis Survivors after Discharge: Results from a Prospective, Multicenter Study.

Objective: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are major public health and social issues worldwide. The long-term follow-up of COVID-19 with pulmonary TB (PTB) survivors after discharge is unclear. This study aimed to comprehensively describe clinical outcomes, including sequela and recurrence at 3, 12, and 24 months after discharge, among COVID-19 with PTB survivors. Methods: From January 22, 2020 to May 6, 2022, with a follow-up by August 26, 2022, a prospective, multicenter follow-up study was conducted on COVID-19 with PTB survivors after discharge in 13 hospitals from four provinces in China. Clinical outcomes, including sequela, recurrence of COVID-19, and PTB survivors, were collected via telephone and face-to-face interviews at 3, 12, and 24 months after discharge. Results: Thirty-two COVID-19 with PTB survivors were included. The median age was 52 (45, 59) years, and 23 (71.9%) were men. Among them, nearly two-thirds (62.5%) of the survivors were moderate, three (9.4%) were severe, and more than half (59.4%) had at least one comorbidity (PTB excluded). The proportion of COVID-19 survivors with at least one sequela symptom decreased from 40.6% at 3 months to 15.8% at 24 months, with anxiety having a higher proportion over a follow-up. Cough and amnesia recovered at the 12-month follow-up, while anxiety, fatigue, and trouble sleeping remained after 24 months. Additionally, one (3.1%) case presented two recurrences of PTB and no re-positive COVID-19 during the follow-up period. Conclusion: The proportion of long symptoms in COVID-19 with PTB survivors decreased over time, while nearly one in six still experience persistent symptoms with a higher proportion of anxiety. The recurrence of PTB and the psychological support of COVID-19 with PTB after discharge require more attention.

Daily Associations of Air Pollution and Pediatric Asthma Risk Using the Biomedical REAI-Time Health Evaluation (BREATHE) Kit.

BACKGROUND: Exposure to air pollution is associated with acute pediatric asthma exacerbations, including reduced lung function, rescue medication usage, and increased symptoms; however, most studies are limited in investigating longitudinal changes in these acute effects. This study aims to investigate the effects of daily air pollution exposure on acute pediatric asthma exacerbation risk using a repeated-measures design. METHODS: We conducted a panel study of 40 children aged 8-16 years with moderate-to-severe asthma. We deployed the Biomedical REAI-Time Health Evaluation (BREATHE) Kit developed in the Los Angeles PRISMS Center to continuously monitor personal exposure to particulate matter of aerodynamic diameter < 2.5 µm (PM2.5), relative humidity and temperature, geolocation (GPS), and asthma outcomes including lung function, medication use, and symptoms for 14 days. Hourly ambient (PM2.5, nitrogen dioxide (NO2), ozone (O3)) and traffic-related (nitrogen oxides (NOx) and PM2.5) air pollution exposures were modeled based on location. We used mixed-effects models to examine the association of same day and lagged (up to 2 days) exposures with daily changes in % predicted forced expiratory volume in 1 s (FEV1) and % predicted peak expiratory flow (PEF), count of rescue inhaler puffs, and symptoms. RESULTS: Participants were on average 12.0 years old (range: 8.4-16.8) with mean (SD) morning %predicted FEV1 of 67.9% (17.3%) and PEF of 69.1% (18.4%) and 1.4 (3.5) puffs per day of rescue inhaler use. Participants reported chest tightness, wheeze, trouble breathing, and cough symptoms on 36.4%, 17.5%, 32.3%, and 42.9%, respectively (n = 217 person-days). One SD increase in previous day O3 exposure was associated with reduced morning (beta [95% CI]: -4.11 [-6.86, -1.36]), evening (-2.65 [-5.19, -0.10]) and daily average %predicted FEV1 (-3.45 [-6.42, -0.47]). Daily (lag 0) exposure to traffic-related PM2.5 exposure was associated with reduced morning %predicted PEF (-3.97 [-7.69, -0.26]) and greater odds of "feeling scared of trouble breathing" symptom (odds ratio [95% CI]: 1.83 [1.03, 3.24]). Exposure to ambient O3, NOx, and NO was significantly associated with increased rescue inhaler use (rate ratio [95% CI]: O3 1.52 [1.02, 2.27], NOx 1.61 [1.23, 2.11], NO 1.80 [1.37, 2.35]). CONCLUSIONS: We found significant associations of air pollution exposure with lung function, rescue inhaler use, and "feeling scared of trouble breathing." Our study demonstrates the potential of informatics and wearable sensor technologies at collecting highly resolved, contextual, and personal exposure data for understanding acute pediatric asthma triggers.

Advances in research on SARS-CoV-2

An unexplained pneumonia outbreak at the end of 2019 was found to be associated with a novel coronavirus (SARS-CoV-2). The virus is the seventh known coronavirus that can infect humans. In a short period of time, this coronavirus infection has spread to many regions of the world, causing the concern of countries around the world. At present, related research on SARS-CoV-2 is still in its infancy. This article summarizes the findings of the latest research related to SARS-CoV-2 to provide reference for subsequent research and prevention.

Fast deep learning computer-aided diagnosis of COVID-19 based on digital chest x-ray images (preprint)

Coronavirus disease 2019 (COVID-19) is a novel harmful respiratory disease that has rapidly spread worldwide. At the end of 2019, COVID-19 emerged as a previously unknown respiratory disease in Wuhan, Hubei Province, China. The world health organization (WHO) declared the coronavirus outbreak a pandemic in the second week of March 2020. Simultaneous deep learning detection and classification of COVID-19 based on the full resolution of digital X-ray images is the key to efficiently assisting patients by enabling physicians to reach a fast and accurate diagnosis decision. In this paper, a simultaneous deep learning computer-aided diagnosis (CAD) system based on the YOLO predictor is proposed that can detect and diagnose COVID-19, differentiating it from eight other respiratory diseases: atelectasis, infiltration, pneumothorax, masses, effusion, pneumonia, cardiomegaly, and nodules. The proposed CAD system was assessed via five-fold tests for the multi-class prediction problem using two different databases of chest X-ray images: COVID-19 and ChestX-ray8. The proposed CAD system was trained with an annotated training set of 50,490 chest X-ray images. The regions on the entire X-ray images with lesions suspected of being due to COVID-19 were simultaneously detected and classified end-to-end via the proposed CAD predictor, achieving overall detection and classification accuracies of 96.31% and 97.40%, respectively. Most test images from patients with confirmed COVID-19 and other respiratory diseases were correctly predicted, achieving average intersection over union (IoU) greater than 90%. Applying deep learning regularizers of data balancing and augmentation improved the COVID-19 diagnostic performance by 6.64% and 12.17% in terms of the overall accuracy and the F1-score, respectively. It is feasible to achieve a diagnosis based on individual chest X-ray images with the proposed CAD system within 0.0093 s. Thus, the CAD system presented in this paper can make a prediction at the rate of 108 frames/s (FPS), which is close to real-time. The proposed deep learning CAD system can reliably differentiate COVID-19 from other respiratory diseases. The proposed deep learning model seems to be a reliable tool that can be used to practically assist health care systems, patients, and physicians.